达罗他胺对非转移性去势抵抗性前列腺癌患者健康相关生活质量的影响:ARAMIS III期试验分析
ARAMIS试验中,达罗他胺联合雄激素剥夺治疗(ADT)较安慰剂联合ADT显著改善非转移性去势抵抗性前列腺癌(nmCRPC)患者的无转移生存(MFS)、总生存(OS)和至疼痛进展时间。本分析显示,达罗他胺显著延长FACT-P前列腺癌子量表(PCS)至恶化时间(HR 0.80,95%CI 0.70-0.91;P=0.0005),并延迟EORTC QLQ-PR25泌尿症状(HR 0.64,95%CI 0.54-0.76;P<0.0001)和肠道症状(HR 0.78,95%CI 0.66-0.92;P=0.0027)至恶化时间,激素治疗相关症状至恶化时间两组相似。
要点
- 达罗他胺显著延长前列腺癌特异性生活质量(FACT-P PCS)至恶化时间(HR 0.80,P=0.0005)。
- 达罗他胺显著延迟EORTC QLQ-PR25泌尿症状(HR 0.64)和肠道症状(HR 0.78)至恶化时间。
- 激素治疗相关症状至恶化时间两组相似。
核心结论
- 在通常无症状的nmCRPC患者中,达罗他胺通过显著延迟前列腺癌特异性生活质量和疾病相关症状的恶化,维持了健康相关生活质量。
研究设计与样本
- 双盲、安慰剂对照的III期ARAMIS试验,随机纳入前列腺特异性抗原倍增时间≤10个月的nmCRPC患者,接受达罗他胺600 mg每日两次(n=955)或匹配安慰剂(n=554),同时继续ADT。
- 主要终点为无转移生存(MFS);次要终点包括总生存(OS)和至疼痛进展时间;本分析评估健康相关生活质量(HRQoL)。
主要发现
- 主要分析(数据截止日期:2018年9月3日)显示,达罗他胺较安慰剂显著延长FACT-P PCS至恶化时间(HR 0.80,95%CI 0.70-0.91;P=0.0005)。
- EORTC QLQ-PR25结果显示,达罗他胺较安慰剂显著延迟泌尿症状至恶化时间(HR 0.64,95%CI 0.54-0.76;P<0.0001)和肠道症状至恶化时间(HR 0.78,95%CI 0.66-0.92;P=0.0027)。
- 激素治疗相关症状至恶化时间两组相似。
关键数值与推荐
- FACT-P PCS至恶化时间:达罗他胺 vs 安慰剂 HR 0.80(95%CI 0.70-0.91;P=0.0005)。
- EORTC QLQ-PR25泌尿症状至恶化时间:HR 0.64(95%CI 0.54-0.76;P<0.0001)。
- EORTC QLQ-PR25肠道症状至恶化时间:HR 0.78(95%CI 0.66-0.92;P=0.0027)。
临床怎么用
- 对于通常无症状的nmCRPC患者,达罗他胺联合ADT在改善生存结局的同时,可维持或延缓健康相关生活质量的恶化。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: In the ARAMIS trial, darolutamide plus androgen deprivation therapy (ADT) versus placebo plus ADT significantly improved metastasis-free survival (MFS), overall survival (OS) and time to pain progression in patients with non-metastatic castration-resistant prostate cancer (nmCRPC). Herein, we present analyses of patient-reported health-related quality of life (HRQoL) outcomes. PATIENTS AND METHODS: This double-blind, placebo-controlled, phase III trial randomised patients with nmCRPC and prostate-specific antigen doubling time ≤10 months to darolutamide 600 mg (n = 955) twice daily or matched placebo (n = 554) while continuing ADT. The primary end-point was MFS; the secondary end-points included OS and time to pain progression. In this analysis, HRQoL was assessed by the time to deterioration using the Functional Assessment of Cancer Therapy-Prostate (FACT-P) prostate cancer subscale (PCS) and the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Prostate Cancer Module (EORTC QLQ-PR25) subscales. RESULTS: Darolutamide significantly prolonged time to deterioration of FACT-P PCS versus placebo (hazard ratio [HR] 0.80, 95% confidence interval [CI] 0.70-0.91; P = 0.0005) at the primary analysis (cut-off date: 3rd September 2018). Time to deterioration of EORTC QLQ-PR25 outcomes showed statistically significant delays with darolutamide versus placebo for urinary (HR 0.64, 95% CI 0.54-0.76; P < 0.0001) and bowel (HR 0.78, 95% CI 0.66-0.92; P = 0.0027) symptoms. Time to worsening of hormonal treatment-related symptoms was similar between the two groups. CONCLUSION: In patients with nmCRPC who are generally asymptomatic, darolutamide maintained HRQoL by significantly delaying time to deterioration of prostate cancer-specific quality of life and disease-related symptoms versus placebo.
引用
- Smith MR, Shore N, Tammela TL, et al. Darolutamide and health-related quality of life in patients with non-metastatic castration-resistant prostate cancer: An analysis of the phase III ARAMIS trial. Eur J Cancer. 2021. PMID: 34273811. doi:10.1016/j.ejca.2021.06.010
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。